Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724202 · ClinicalTrials.gov registry record · Early Phase 1
Curcumin in Combination With 5FU for Colon Cancer
A Early Phase 1 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT02724202: Clinical Trial Early Phase 1 study, sponsored by Baylor Research Institute.
NCT02724202 is a Early Phase 1 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02724202, a Early Phase 1 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what effects (good and bad) that the combined treatments have on colon cancer.
Primary Outcome
Events will be recorded from the time of informed consent signature through the 30 days following the last study treatment.
Interventions
- DRUG Curcumin
- DRUG 5-flurorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2020-01-10 |
| Phase | Early Phase 1 |
Why NCT02724202 stopped before completion
NCT02724202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Curcumin is the first listed.
NCT02724202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02724202 about?
NCT02724202 is a clinical study titled "Curcumin in Combination With 5FU for Colon Cancer". The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what effects (good and bad) that the combined treatments have on colon cancer.
What is the current status of trial NCT02724202?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2018-02-20. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT02724202?
The interventions under investigation include: Curcumin (DRUG), 5-flurorouracil (DRUG).
Who is sponsoring clinical trial NCT02724202?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02724202's enrollment target sits among peer trials
15 1403rd of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI